RGEN
Repligen Corporation
RGEN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover.
RGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
RGEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
RGEN PE Valuation
RGEN has no meaningful PE right now: it lost money over the past year.
RGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for RGEN, but weaker profitability.
RGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.43 | -16% |
| Q3 2022 | $2.90 | +38% |
| Q2 2022 | $2.77 | +55% |
| Q1 2022 | $2.53 | +74% |
| Q4 2021 | $2.24 | +102% |
| Q3 2021 | $2.10 | +156% |
| Q2 2021 | $1.79 | +209% |
| Q1 2021 | $1.45 | +222% |
| Q4 2020 | $1.11 | +152% |
RGEN's earnings per share have climbed steadily: $2.90 over the past year, up 38% from the year before, and higher year over year every quarter since late 2020.
RGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $204.1M | +12% |
| Q1 2026 | $194.3M | +15% |
| Q4 2025 | $197.9M | +18% |
| Q3 2025 | $188.8M | +22% |
| Q2 2025 | $182.4M | +15% |
| Q1 2025 | $169.2M | +10% |
| Q4 2024 | $167.5M | +0.6% |
RGEN's revenue has grown year over year for nine quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -23 points |
| Q2 2026 | 6.8% | -0.8 points |
| Q1 2026 | 8.2% | +4.3 points |
| Q4 2025 | 9% | +31 points |
| Q3 2025 | 8.9% | +14 points |
| Q2 2025 | 7.6% | +4.2 points |
| Q1 2025 | 3.9% | +1.4 points |
| Q4 2024 | -22% | -28 points |
RGEN's operating margin was −14% last quarter, down 23 points from the same quarter a year ago, near the bottom of its range since 2019.
RGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.2M | -12% |
| Q2 2026 | $27.4M | +28% |
| Q1 2026 | $23.6M | +106% |
| Q4 2025 | $17.6M | -48% |
| Q3 2025 | $43.4M | +2.5% |
| Q2 2025 | $21.5M | -42% |
| Q1 2025 | $11.4M | -69% |
| Q4 2024 | $33.6M | +87% |
RGEN generated $107M in free cash flow over the past year, down 3% from the year before.
RGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -80K shares |
| 1 year | -1.4% | -810K shares |
RGEN has 57M diluted shares, down 1.4% from a year ago.
RGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -2.7x | Net Cash |
| Q2 2025 | -14.0x | Net Cash |
| Q1 2025 | -17.8x | Net Cash |
| Q4 2024 | -21.9x | Net Cash |
RGEN has more cash than debt.
RGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 48.9 | Neutral |
RGEN's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
RGEN PE vs Healthcare Sector
| Metric | RGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGEN has no meaningful PE right now: it lost money over the past year.
RGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $176.8 | 5.8% below |
| 20 week MA | $166.0 | 0.3% above |
| 50 week MA | $147.6 | 13% above |
| 100 week MA | $142.8 | 17% above |
| 200 week MA | $152.1 | 9.5% above |
RGEN has slipped below its 8-week average, but it's still above the other four, and 9.5% above its 200-week average.
RGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.2 | $195.7 | +112% |
| 2021 | $195.7 | $264.7 | +35% |
| 2022 | $264.7 | $167.5 | -37% |
| 2023 | $167.5 | $179.8 | +7.3% |
| 2024 | $179.8 | $145.5 | -19% |
| 2025 | $145.5 | $166.2 | +14% |
| 2026 YTD | $166.2 | $166.5 | +0.2% |
RGEN has finished higher in four of the last six years. It's roughly flat so far in 2026.